This process can be blocked by the inhibition of MEK1/2 (trametinib), JNK (SP600125) or anti-PD-L1 antibody (Fig. 7), suggesting the importance of combinational therapy for MLN4924-based cancer treatment. This evidence concerns the gene MAP2K1 and cancer.